FDA CDER chief says expanding generic GLP-1 drugs is top priority to cut American costs

Michael Davis, director of the FDA's Center for Drug Evaluation and Research, highlighted that increasing the supply of generic GLP-1 medicines is a key focus for the agency.

He noted that broader availability of these generics could help lower the price of GLP-1 treatments for patients in the United States.

The comments addressed scientific and legal hurdles companies encounter when attempting to bring generic versions of GLP-1 drugs to market.

The remarks were included in the "This Week at FDA" briefing, which also mentioned a Senate confirmation hearing and a new rule intended to reduce animal testing.